VivoSeq
Oncology

Solid Tumor Cancer

5

Pipeline Programs↗

7

Active Trials↗

5

Companies Involved↗

Solid Tumor Cancer is an early-stage landscape with 5 programs across 5 companies. The most active players are Johnson & Johnson, Gynecologic Oncology Group, Bristol-Myers Squibb.

Intelligence

Pipeline Metrics

Competitive Density

34/100

Pipeline Velocity

19/100

Mech. Concentration

50/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Johnson & Johnson logo

Johnson & Johnson

1 program

Phase 2G

Gynecologic Oncology Group

1 program

Phase 2Bristol-Myers Squibb logo

Bristol-Myers Squibb

1 program

Phase 2A

Avenzo Therapeutics, Inc.

2 programs

PreclinicalM

Monopar Therapeutics

0 programs

Preclinical

Pipeline

Programs by Phase

Analysis

Trial Status

12

clinical trials

Completed4 · 33%
Recruiting4 · 33%
Enrolling by invitation1 · 8%
Available1 · 8%
Active, not recruiting1 · 8%
Not yet recruiting1 · 8%

Clinical Trials

Trial Activity

12 trials

A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT05859074·56 enrolled
A Study of Repotrectinib in Combination With Chemotherapy in Children and Young Adults With Solid Tumor Cancer
Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 1/2·NCT05004116·77 enrolled
A Phase 1/2, First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of AVZO-103, a Nectin4/Trop2 ADC, as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Recruiting·AAvenzo Therapeutics, Inc.·Preclinical·NCT07193511·355 enrolled
GEMINI: Phase II Study Using Metronomic Gemcitabine, Mitomycin C, and Thalidomide for Advanced Solid Tumors
Recruiting·SSarcoma Oncology Research Center, LLC·Phase 2·NCT07671534·60 enrolled
A Study of RP-3500 in Combination With Standard Radiation Therapy in People With Solid Tumor Cancer
Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 1/2·NCT05566574·49 enrolled
Development of an Artificial Intelligence-Driven Novel Response Evaluation Framework and Its Biological Characterization
Not yet recruiting·SShanghai Zhongshan Hospital·N/A·NCT07685548·6,120 enrolled
Exceptional Responders With Solid Tumor Cancer to Chemotherapy
Enrolling by invitation·AAdera Labs, LLC·N/A·NCT02555735·250 enrolled
Solid Tumor Cancer Surgery With or Without Intraoperative Imaging: A Registry
Completed·UUniversity of Pennsylvania·N/A·NCT02852252·291 enrolled
A Study of Mirdametinib on Its Own or in Combination With Fulvestrant in People With Solid Tumor Cancer
Completed·MMemorial Sloan Kettering Cancer Center·Phase 1/2·NCT05054374·6 enrolled
Dose Escalation, First-in-human Clinical Trial to Evaluate the Safety, Pharmacokinetics and Preliminary Antitumor Activity of PEP-010, Administered as Single Agent and in Combination With Paclitaxel or With Gemcitabine in Patients With Metastatic Solid Cancer
Completed·IInstitut Curie·Phase 1·NCT04733027·77 enrolled
Feasibility and Acceptability of the Remote Oncology Symptom Assessment Application
Completed·UUniversity of Pittsburgh·Preclinical·NCT07218874·39 enrolled
MNPR-101-PCTA-177Lu Expanded Access Program (EAP) for Patients With Solid Tumor Cancer
Available·MMonopar Therapeutics·N/A·NCT06980519

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)